



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India
Tel : (02646) 220774
Fax : (02646) 251291
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.
Tel : (91-22) 26701050/1/2
Fax : (91-22) 26701053
Email: samrat@bom4.vsnl.net.in

30 May, 2018

To,
Department of Corporate Services,
Bombay Stock Exchange Limited
25th Floor, P J Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir,

Sub: Audited Financial Results f.t.y.e. 31/03/2018

We write this to inform you that at a Board Meeting held today i.e. Wednesday, the 30th day of May, 2018, the Board has considered and adopted the attached Audited Financial Results of the company for the year ended 31st March, 2018.

Kindly inform all your members.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited

Rajesh Mehta
Director



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat (Website: www.samratpharmachem.com)

Corp Office : 701/702 Business Square, M. A. Road, Andheri (West), Mumbai - 400 058 (CIN: L24230GJ1992PLC017820)

(Rs. in Lakhs)				
Statement of Standalone Audited Results for the Quarter and for the Year Ended 31 MARCH, 2018				
Particulars	Quarter Ended		Year Ended	
	31-Mar-18 (Audited)	31-Mar-17 (Audited)	31-Mar-18 (Audited)	31-Mar-17 (Audited)
1 (a). Revenue from Operations	2,644.73	1,303.56	9,252.01	7,106.50
(b). Other Income	16.35	3.00	24.57	15.85
Total Revenue	2,661.08	1,306.56	9,276.58	7,122.35
2. Expenses				
a) Cost of materials consumed	2,453.33	1,056.55	8,110.77	6,080.31
b) Purchase of Traded Goods	0.00	70.86	131.97	214.60
c) Changes in inventories of FG, WIP & Stock in trade	-49.44	-44.25	-50.56	-27.53
d) Employee Costs	41.22	37.00	129.60	110.00
e) Finance Cost	24.78	12.70	86.35	63.46
f) Depreciation & Amortisation expense	8.89	8.14	41.22	43.05
g) Other Expenses	57.58	82.78	335.21	360.92
Total Expenses	2,536.36	1,223.78	8,784.56	6,844.81
3. Profit before exceptional items and tax	124.72	82.78	492.02	277.54
4. Exceptional Items	0.00	0.00	0.00	0.00
5. Profit before tax	124.72	82.78	492.02	277.54
6. Tax expense				
a) Current Tax	-63.71	-53.56	-168.94	-104.71
b) Deferred Tax	9.24	8.17	-1.41	2.61
7. Profit (Loss) for the period from continuing operations	70.25	37.39	321.67	175.44
8. Profit / (Loss) from discontinuing operations	0.00	0.00	0.00	0.00
9. Tax expense of discontinuing operations	0.00	0.00	0.00	0.00
10. Profit / (Loss) from discontinuing operations after tax	0.00	0.00	0.00	0.00
11. Profit / (Loss) for the period	70.25	37.39	321.67	175.44
12. Other Comprehensive Income (OCI)	0.00	0.00	0.00	0.00
13. Total Comprehensive Income for the period	70.25	37.39	321.67	175.44
14. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97
15. Earnings per equity share (not annualized)				
a) Basic	2.27	1.21	10.41	5.68
b) Diluted	2.27	1.21	10.41	5.68



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Standalone Statement of Assets and Liabilities		
Particulars	As at 31-Mar-18 (Audited)	As at 31-Mar-17 (Audited)
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	695.96	696.88
Capital work-in-progress	0.00	19.94
Intangible assets	2.66	4.58
Intangible assets under development	0.00	0.00
Financial Assets		
Investments	0.00	0.00
Loans	8.71	10.14
Deferred tax assets (net)	0.00	0.00
Other non-current assets	48.88	47.04
Total Non Current Assets	756.21	778.58
Current Assets		
Inventories	684.62	702.14
Financial Assets		
Investments	0.10	0.10
Trade Receivables	2,188.61	1,184.22
Cash and Cash Equivalents	398.11	243.52
Loans	2.26	2.28
Other Financial Assets	0.00	473.68
Other current assets	52.85	223.72
Total Current Assets	3,326.55	2,829.66
Total Assets	4,082.76	3,608.24
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	308.97	308.97
Other Equity	1,544.16	1,222.48
Total Equity	1,853.13	1,531.45
Non-Current Liabilities		
Financial Liabilities		
Borrowings	76.21	116.73
Provisions	0.00	0.00
Deferred Tax Liabilities (Net)	31.42	30.01
Other Non-Current Liabilities	19.63	19.63
Total Non-Current liabilities	127.26	166.37
Current Liabilities		
Financial Liabilities		
Borrowings	862.77	578.55
Trade Payables	1,039.50	730.10
Other Financial Liabilities	0.00	487.72
Other Current Liabilities	59.01	54.41
Provisions	141.09	59.64
Total Current Liabilities	2,102.37	1,910.42
Total Liabilities	4,082.76	3,608.24



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Notes

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The above results have been taken on record by the Board of Directors at its Meeting held on Wednesday, 30 May 2018 at the Corporate Office of the Company.
3. The figures of the quarter ended 31 Mar 2018 and 31 Mar 2017 are the balancing figures between the audited in respect of full financial years and the published (unaudited) up to the third quarter of relevant financial year.
4. The Company has adopted Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from 01 April 2017 (with a transition date of 01 April 2016). Accordingly the financial results for the year ended 31 March 2018 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under section 133 of the Companies Act, 2013.
5. Results for the quarter and year ended 31 March 2017 have been restated to comply with Ind AS to make them comparable.
6. The Company manufactures pharmaceutical chemicals, which is a single business segment.
7. The figures for the previous period have been regrouped where necessary to conform to current period's classification.
8. Reconciliation between standalone financial results reported under erstwhile Indian GAAP and Ind AS:

Description	Quarter ended 31-Mar-17	Year to date 31-Mar-17
Net Profit after tax as per Indian GAAP	24.91	156.56
Ind AS Adjustments		
- Restatement of expense	-2.13	4.27
- Amortization of gain/loss	-5.74	-5.74
- Prior period expense	29.68	29.68
- Tax adjustments (Net)	-9.33	-9.33
Total Comprehensive Income as per Ind AS	37.39	175.44

9. Reconciliation of Equity as reported under erstwhile Indian GAAP and Ind AS:

Description	Year to date 31-Mar-17
Equity reported as per previous GAAP	1,532.17
Ind AS Adjustments	
- Restatement of expense	4.27
- Amortization of gain/loss	-5.33
- Tax adjustments (Net)	0.34
Total Comprehensive Income as per Ind AS	1,531.45

By order of the Board of Directors
For Samrat Pharmachem Limited

Rajesh Mehta
Executive Director

Place : Mumbai
Date : 30 May 2018



Independent Auditor's Report on Quarterly Financial Results and Year to Date Results of Samrat Pharmachem Ltd Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors,
Samrat Pharmachem Limited**

We have audited the quarterly financial results of Samrat Pharmachem Limited for the quarter ended on 31st March 2018 and the year to date results for the period from 01st April 2017 to 31st March 2018 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Attention is drawn to the fact that the figures for the quarter ended 31st March 2018 and the corresponding quarter ended in the previous year as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the published year to date figures upto the end of third quarter of the current and previous financial year respectively. Also the figures upto the end of the third quarter for the current and previous financial year had only been reviewed and not subjected to audit.

These quarterly financial results as well the year to date financial results have been prepared on the basis of the reviewed financial results upto the end of third quarter and audited annual Ind AS financial statements respectively, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such Ind AS financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that our audit provides a reasonable basis of our opinion.

In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as year to date results:

- a. as presented in accordance with requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in this regard and
- b. give true and fair view of the net profit and other financial information for the quarter ended March 31, 2018 as well as the year to date results for the period from 01st April 2017 to 31st March 2018.

For Shah & Sayla LLP

Chartered Accountants

FRN :109364W



MIRAL H. NAGDA

(PARTNER)

Membership No. 108135

Place: Mumbai

Date: 30th May 2018



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Corporate Office

[Handwritten signature]

